Italy Massimo Scaccabarozzi, President of Farmindustria, discusses Italy’s response to the pandemic and the association’s key priorities, which include maintaining Italy’s position as a European leader in terms of production. Italy has a key role to play in the EU objective of guaranteeing continuity of supply during emergencies. Italy became…
Australia Writing in April edition of DIA’s Global Forum magazine, the University of New South Wales’s Richard Day looks at Australia’s National Medicines Policy (NMP) and how it is being reshaped by community and stakeholder feedback. Australia’s National Medicines Policy (NMP), gazetted in 2000, is being revised and the draft policy was…
Europe When the COVID-19 pandemic struck in early 2020, Europe’s reliance on active pharmaceutical ingredient (API) and generic medicine suppliers outside of the continent was laid bare. In the face of crisis, countries like India and China understandably looked first to safeguard their own populations which, combined with supply chain strains…
China As China struggles to maintain its ‘dynamic zero-COVID’ policy in the face of Omicron variant outbreaks, other key talking points emerging from the world’s second-largest healthcare and life sciences market include Chinese firms’ deals to manufacture generic versions of Pfizer’s COVID antiviral, Kintor’s 229 percent share price leap after positive…
Global UNICEF is forecasting that between 16.8 billion and 20.9 billion COVID-19 vaccine doses will be produced in 2022. The Economist Intelligence Unit highlights the drivers of this incredible demand as the fact that booster shots will be needed to counter new variants; the increased number of countries requesting the Pfizer…
India The latest healthcare and pharma news from India, including the opening up of COVID-19 vaccine booster shots to all adults; the lowering of vaccine prices; and the licences granted to 19 Indian pharmaceutical firms for the generic version of Pfizer’s oral antiviral COVID-19 pill. COVID-19 vaccine booster shots now…
Global Antimicrobial pollution is a major global health and environmental risk. Shawview Consulting’s Brendan Shaw and Nicolai Schaaf of SIWI uncover what antibiotics manufacturers are doing about it. Last month, global leaders issued an urgent call for all countries to reduce antimicrobial pollution. This includes the safe disposal of antimicrobial…
Global In 2022 global healthcare will continue to feel the effects of the pandemic and although COVID-19 has become less virulent, with the global death rate down to 0.4 percent from an initial peak of about three percent, new variants are still set to emerge this year. At the Economist Intelligence…
Adl Biopharma ADL Biopharma is a Spanish CDMO and, according to its CEO, owner of Europe’s largest fermenter. Ignacio Urbelz, CEO, reveals how, after a tumultuous time that saw the company go bankrupt in 2013 and change ownership in 2020, the organization has reorganized with the intention of returning to its 1990s…
UAE The Managing Director of Dubai Science Park (DSP), Marwan Abdulaziz Janahi, comments on Dubai’s success in becoming a regional hub for life sciences companies, the challenging reality of localizing high-tech manufacturing, and the move towards specialized centers of excellence within Dubai’s hospital infrastructure. The community DSP is building comprises…
China Bridge Consulting’s Zoe Leung examines the journeys of Chinese-developed COVID-19 vaccines outside of China’s borders, drawing on a number of examples, from Sinopharm’s work on boosting vaccine supply in the UAE to Sinovac’s Egyptian and Chilean partnerships, CanSino’s steady progress in Pakistan and Mexico, and Zhifei Longcom’s Uzbek success.* …
Global The top COVID-19 Vaccines by revenue in 2021 and sales projections for 2022 based on Airfinity’s COVID-19 Vaccine Market Revenue Forecast 2022. Pfizer/BioNTech’s vaccine stands to make USD 42.69 billion in 2022, while Moderna’s product has projected sales of USD 25.71 billion. Projected USD 3.97 billion sales for Russia’s Sputnik…
See our Cookie Privacy Policy Here
